Profile: Interleukin Genetics Inc (ILIU.PK)

ILIU.PK on OTC Markets Group

0.14USD
4 May 2015
Change (% chg)

-- (--)
Prev Close
$0.14
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
50,155
52-wk High
$0.46
52-wk Low
$0.05

Search Stocks

Interleukin Genetics, Inc., incorporated on March 28, 2000, is a personalized health company, which develops genetic tests to provide information to manage health and specific health risks. The Company’s business focuses on personalized health, by providing genetic tests clinical value. The Company’s genetic tests include PerioPredict genetic test analyzes genetic variations associated with inflammation and identifies individuals who are at increased risk for more severe periodontal disease; weight management genetic test determines whether a low fat, low carbohydrate or balanced diet may normal or vigorous exercise is needed to lose existing body fat; bone health genetic test is designed to identify whether an individual is more likely to be susceptible to spine fractures and low bone mineral density associated with osteoporosis; heart health genetic test is designed to identify genetic predisposition to excess inflammation, which is a risk factor for heart attack; nutritional needs genetic test is designed to identify deoxyribonucleic acid (DNA) variations in genes crucial to B-vitamin metabolism and the ability to manage oxidative stress and, wellness select genetic test allows buyers to purchase any combination of inherent health genetic tests at a discounted price. The Company markets its genetic tests under Inherent Health brand.

Genetic Test for Risk of Periodontal Disease

PerioPredict genetic test analyzes genetic differences that are related with inflammation and identifies individuals with increased risk for more severe periodontal disease. The PerioPredict genetic test identifies specific polymorphisms (genetic variations) in genes that regulate the production of interleukin cytokines. Interleukin-1 (IL-1) is the critical regulators of periodontal disease and studies in non-human primates have shown that drugs specifically blocking IL-1 alone or IL-1 plus TNFa dramatically and significantly reduce tissue destruction even when the bacterial challenge is not reduced.

Inherent Health Brand of Genetic Tests

Weight management genetic test helps take the guesswork out of finding an effective diet and exercise solution by revealing actionable steps to achieve weight goals based on genetics. The test provides new information beyond traditional assessments, so that nutritional intake and fitness routines can be tailored for improved, sustainable results. This test identifies five SNPs in four human genes: fatty acid binding protein 2 (FABP2), adrenergic receptor beta 2 (ADRB2 –two variations), adrenergic receptor beta 3 (ADRB3) and peroxisome proliferator-activated receptor gamma (PPAR- γ).

The Company conducted a number of studies that demonstrate a gene-diet interaction based on the multi-locus patterns. The first study, completed in 2010, involved subjects who originally participated in Stanford University’s A TO Z weight loss study. Individuals from the A TO Z study were contacted to participate in this retrospective genotype-diet interaction study. In the original study, 311 overweight/obese (body mass index, 27-40 kilograms/square meter), nondiabetic, premenopausal, generally healthy women were randomly assigned for 12 months to either the Atkins-like (very low carbohydrate), Zone-like (low carbohydrate), LEARN-like (balanced) or Ornish-like (low fat) diets for the primary purpose of losing weight. The extensive data collected in that study included dietary intake assessment (three unannounced 24-hour recalls for each time point administered by a dietitian and analyzed using NDS-R, University of Minnesota), anthropometric measures including weight, and related physiological variables, all collected at baseline, two, six and 12 months.

The Company’s bone health genetic test is designed to identify individuals associated with osteoporosis. Although it typically starts later in life, early intervention can help prevent osteoporosis. Preventive measures can reduce the risk for bone loss and fractures, which in the case of vertebral fractures leads to a hunched over appearance. The test identifies single nucleotide polymorphisms (SNP) in each of three genes involved in processes that affect bone; estrogen receptor alpha (ER1 Xba1), vitamin D receptor (VDR), and interleukin-1 (IL-1). Certain patterns of variations are associated with increased risk of spine fracture and/or low bone mineral density. The test can be used as an aid to making diet, exercise and other lifestyle choices to maintain and improve bone health.

The Company’s heart health genetic test is designed to identify risk factor for heart attack. The genetic analysis identifies individuals that have a lifelong tendency to overproduce certain chemicals in the body that lead to inflammation. Overproduction of these chemicals may start a chain reaction that ultimately may lead to a heart attack. Knowing genetic risk enables individuals to take specific actions to decrease overall risk. The test identifies three SNPs in two genes involved in inflammation, IL-1 alpha and IL-1 beta. Certain IL-1 variations are associated with increased inflammation, which is a risk factor for early heart attack. The test may be used as an aid to making diet, exercise, and other lifestyle choices to reduce inflammation-based risk.

The Company’s nutritional needs genetics test is designed to identify DNA variations in genes. Individuals with certain variations in these genes may be at increased risk for ineffective utilization of B-vitamins and potential for cell damage caused by oxidative stress, both of which can in some cases lead to increased risk for certain diseases. The test identifies the presence or absence of human genotypic markers methylenetetrahydrofolate reductase (MTHFR) and transcobalamin II (TCN2) involved in vitamin B metabolism and markers superoxide dismutase 2 (SOD2), glutathione S-transferase 1 deletions (GSTM1), paraoxonase 1 (PON1), X-ray repair cross complementing group 1 (XRCC1) in response to oxidative stress. Certain variations are associated with less efficient B-vitamin metabolism or reduced activity of endogenous anti-oxidant systems. The test may be used to aid individuals in deciding whether to supplement their diet with B vitamins and/or antioxidants.

Genetic Test Pipeline

The Company’s osteoarthritis genetic test is designed to identify joint diseases. Osteoarthritis (OA) is the common adult joint disease, increasing in frequency and severity in all aging populations. The estimated the United States prevalence is 20-40 million patients or five times that of rheumatoid arthritis. The common forms of OA involve the hand, knee, hip and spine.

Company Address

Interleukin Genetics Inc

135 Beaver Street
WALTHAM   MA   02452
P: +1781.3980700
F: +1781.3980720

Company Web Links

Search Stocks